2024 ACA Nashville Program Book_154th Congress of Correction

Speakers: Gerald Jorgenson , Director of Healthcare Compliance, Kansas Department of Corrections, Topeka, Kansas; Kathy Derby , Vice President of Sales and Marketing, Clinical Solutions Pharmacy, Franklin, Tennessee; Katie Schmidt , Vice President of Operations, Centurion Health, Topeka, Kansas How to Successfully Pass a DEA Audit for a Correction-Based OTP Program [CE/CME] Room 203B Primary Area of Focus: Healthcare & Wellness Primary Community of Focus: Prisons & Jails The most common reason for incarceration is related to minor drug offenses, mostly opioids. More and more correctional facilities are providing access to MOUD through medication-assisted programs (MAT), but many fall short of establishing a full opioid treatment program (OTP) due to the many regulatory challenges. According to federal law, Corrections-based OTPs must be certified by not only the Substance Abuse and Mental Health Services Administration (SAMHSA) but they must also be licensed by their State Board of Pharmacy and the Drug Enforcement Agency (DEA). This presentation will discuss the DEA’s regulatory framework for opioid treatment programs in corrections. Specific DEA audit indicators such as controlled substance storage, inventory management, record-keeping, the use of DEA 222 forms, diversion control program, unused controlled substance disposal and the DEA reporting requirement for controlled medication theft will be discussed. The presentation will finally conclude with how to prepare for a DEA audit by utilizing a controlled substance audit checklist as a continuous improvement initiative for a correction based opioid treatment program. Learning Objectives: • Participants will be able to describe the DEA regulatory framework that guides the use of MOUD in OTP programs in corrections. • Participants will be able to discuss the diversion control plan necessary for a successful DEA OTP audit in corrections.

• Participants will be able to describe a continuous education initiative for meeting the DEA’s OTP audit requirements in corrections. Moderator: William (Todd) Kramer , M.S., CCHP-A, CCHP, Director of Policy and Standards Compliance, Delaware Department of Corrections, Dover, Delaware Speakers: Crosby Amoah , PharmD, BCPS, CCHP, Director of Clinical Pharmacy Program, Correct Rx Pharmacy Services, Hanover, Maryland; Rachel L. Legg , PharmD, Clinical Pharmacist, Correct Rx Pharmacy Services, Hanover, Maryland Medication for Opioid Use Disorder: Achieving Collaborative Success and Improving Outcomes Across Correctional Disciplines [CE/CME/CERP/CEU] Room 205B Primary Area of Focus: Healthcare & Wellness/ Special Populations Primary Community of Focus: Adult Corrections/ Prisons & Jails Across the U.S., opioid use and overdose deaths are at epidemic proportions. In 2017, 2.1 million people in the United States had an opioid use disorder (OUD) and nearly 68% of overdose deaths involved an opioid. Opioid overdose deaths have reduced the expected life span of justice-involved people in the U.S., largely due to the risks associated with community reentry following incarceration. MOUD in correctional settings should involve multi-disciplinary teams of health, behavioral health and security professionals. By incorporating multidisciplinary teams into MOUD programs for justice-involved individuals, collaborative and informed decisions about the person’s treatment can be made. This multidisciplinary panel discussion is sponsored by ACA’s Behavioral Health and Substance Use Disorders committees. Participants will have an opportunity to hear from and ask each speaker questions. Learning Objectives: • Participants will understand the effectiveness of MOUD for substance abuse disorders among correctional populations. • Participants will understand the unique

WORKSHOPS Friday, Aug. 16 ▼ 9–10:15 a.m.

106 — ACA 154 th Congress of Correction | Nashville